{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Louisville&page=4&state=Kentucky", "query": { "state": "Kentucky", "city": "Louisville", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 5300, "total_pages": 530, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Louisville&page=5&state=Kentucky&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Louisville&page=3&state=Kentucky&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T09:03:21.425Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06898450", "title": "A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors Cancer", "MSI-H Cancer" ], "interventions": [ { "name": "NDI-219216", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nimbus Wadjet, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 134, "start_date": "2025-03-31", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-17T09:03:21.425Z", "location_count": 11, "location_summary": "Los Angeles, California • Chicago, Illinois • Louisville, Kentucky + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Ithaca", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06898450" }, { "nct_id": "NCT04052997", "title": "Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Camidanlumab Tesirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 117, "start_date": "2019-09-13", "completion_date": "2023-01-19", "has_results": true, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-10-17T09:03:21.425Z", "location_count": 24, "location_summary": "Scottsdale, Arizona • Duarte, California • San Francisco, California + 19 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04052997" }, { "nct_id": "NCT01799824", "title": "Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Axillary Hyperhidrosis" ], "interventions": [ { "name": "ANT-1403", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Anterios Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 52, "start_date": "2013-02", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-12-10", "last_synced_at": "2026-10-17T09:03:21.425Z", "location_count": 9, "location_summary": "Miami, Florida • Pinellas Park, Florida • West Palm Beach, Florida + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Pinellas Park", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "East Windsor", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01799824" }, { "nct_id": "NCT02785913", "title": "Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Taselisib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2014-11", "completion_date": "2019-11", "has_results": true, "last_update_posted_date": "2020-10-23", "last_synced_at": "2026-10-17T09:03:21.425Z", "location_count": 1106, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 688 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02785913" }, { "nct_id": "NCT01289015", "title": "Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tinea Pedis" ], "interventions": [ { "name": "NAFT-600 ( naftin 2 % gel )", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merz North America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 855, "start_date": "2011-02", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2013-09-26", "last_synced_at": "2026-10-17T09:03:21.425Z", "location_count": 22, "location_summary": "Phoenix, Arizona • San Diego, California • San Francisco, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289015" }, { "nct_id": "NCT03898479", "title": "Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alopecia Areata" ], "interventions": [ { "name": "CTP-543", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1000, "start_date": "2019-04-04", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-17T09:03:21.425Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03898479" }, { "nct_id": "NCT00398580", "title": "28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypogonadism", "Hypogonadism, Male" ], "interventions": [ { "name": "Nanomilled testosterone", "type": "DRUG" }, { "name": "Nanomilled dutasteride", "type": "DRUG" }, { "name": "commercially available dutasteride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "MALE", "summary": "18 Years to 70 Years · Male only" }, "enrollment_count": 43, "start_date": "2006-10", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-17T09:03:21.425Z", "location_count": 7, "location_summary": "Torrance, California • Louisville, Kentucky • Baltimore, Maryland + 3 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Durham", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00398580" }, { "nct_id": "NCT06948318", "title": "A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immune Thrombocytopenic Purpura (ITP)" ], "interventions": [ { "name": "Mezagitamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-08-14", "completion_date": "2029-07-29", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-17T09:03:21.425Z", "location_count": 25, "location_summary": "Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948318" }, { "nct_id": "NCT05571059", "title": "Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Ifetroban Sodium", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 128, "start_date": "2024-01-31", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-17T09:03:21.425Z", "location_count": 20, "location_summary": "La Mesa, California • San Francisco, California • Farmington, Connecticut + 17 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05571059" }, { "nct_id": "NCT02268279", "title": "Pharmacokinetics and Safety of Solithromycin in Adolescents and Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bacterial Infection" ], "interventions": [ { "name": "solithromycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Melinta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 84, "start_date": "2015-01", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2017-06-09", "last_synced_at": "2026-10-17T09:03:21.425Z", "location_count": 31, "location_summary": "Little Rock, Arkansas • Orange, California • Palo Alto, California + 28 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02268279" } ] }